Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple dose safety, tolerability and PK of BI 1323495 in healthy Japanese males, including itraconazole DDI
jRCT2071200056Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1323495 (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: SRD safety and tolerability (drug-related adverse events), DDI pharmacokinetics (Cmax and AUC0-∞ of BI 1323495) and 1 more. Started Nov 2020; status: completed.
02
Drugs
BI 1323495
Beyond the preview
Go deeper on jRCT2071200056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200056.